From Marginal to Central: Marginal Zone-like B Cells as Critical Targets in Cladribine-Treated Multiple Sclerosis - Report - MDSpire

Transitioning from Marginal to Central: The Role of Marginal Zone-like B Cells as Key Targets in Multiple Sclerosis Patients Treated with Cladribine

  • By

  • Marta Pirronello

  • Mario Picozza

  • Gisella Guerrera

  • Silvia Corbisiero

  • Andrea Misiti

  • Roberta C. Placido

  • Alice Verdiani

  • Lorenzo de Marco

  • Manolo Sambucci

  • Elena Olivieri

  • Daniela F. Angelini

  • Esmeralda Quartuccio

  • Luca Prosperini

  • Carla Tortorella

  • Maria C. Buscarinu

  • Valeria Zancan

  • Francesca de Masi

  • Marco Salvetti

  • Claudio Gasperini

  • Giovanna Borsellino

  • Luca Battistini

  • June 18, 2026

Share

Clinical Report: Transitioning from Marginal to Central in MS Treatment

Overview

This study investigates the role of marginal zone-like B cells in multiple sclerosis (MS) patients treated with cladribine, highlighting their proinflammatory capacity and slow reconstitution post-treatment. The findings suggest that targeting these B cell subsets may be crucial for enhancing treatment efficacy.

Background

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by demyelination and neurodegeneration, with B cells playing a significant role in its pathogenesis. The advent of B cell-targeted therapies has transformed MS management, emphasizing the need to understand the dynamics of B cell subsets in response to treatment. Cladribine, a disease-modifying therapy, specifically affects memory B cells, which are implicated in MS immunopathology.

Data Highlights

ParameterValue
Number of patients36
Median age39 (18–57)
Female patients25
Male patients11

Key Findings

  • Marginal zone-like (MZ-like) memory B cells are preferentially depleted by cladribine and have a significant proinflammatory capacity.
  • DN B cells exhibit an activated phenotype and recover more rapidly than MZ-like B cells after cladribine treatment.
  • The study involved a longitudinal cohort of 36 MS patients to assess B cell subset dynamics over time.
  • Cladribine treatment reshapes the B cell repertoire, favoring naïve B cells while depleting memory subsets.
  • OCBs persist despite treatment, indicating ongoing antibody production from plasma cells.

Clinical Implications

Understanding the specific effects of cladribine on B cell subsets can inform treatment strategies for MS. Targeting MZ-like memory B cells may enhance therapeutic outcomes and reduce disease activity in MS patients.

Conclusion

The findings underscore the importance of marginal zone-like B cells in MS pathology and their potential as therapeutic targets in cladribine treatment.

Related Resources & Content

  1. Pirronello et al., Frontiers in Immunology, 2026 -- Transitioning from Marginal to Central: The Role of Marginal Zone-like B Cells as Key Targets in Multiple Sclerosis Patients Treated with Cladribine
  2. Acta Neuropathologica — B cells producing IL-10 regulate the inflammatory responses of macrophages and microglia in central nervous system autoimmune disorders
  3. Brain — Insights from EBV-specific T-cell Activity Regarding Multiple Sclerosis
  4. Blood Cancer Journal — Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients
  5. Multiple sclerosis in adults: management | Guidance | NICE
  6. From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis
  7. Performance of the 2024 McDonald Criteria in Patients Under Evaluation for Suspected Multiple Sclerosis | Neurology

Original Source(s)

Related Content